While once-weekly tirzepatide is approved for obesity management in adults, its efficacy and safety in adolescents with obesity or overweight accompanied by obesity-related complications remain to be established. To address this gap, a phase 3 randomized clinical trial evaluated once-weekly tirzepatide in combination with a healthy lifestyle intervention in 160 adolescents across 31 centers in Canada, the US, the Czech Republic, Italy, Poland, and Israel. The participants had a mean age of 14.6 years, mean body weight of 109.7 kg, and mean BMI of 38.6.
At week 72, tirzepatide was associated with an 18.5% reduction in BMI, compared with a 0.5% increase with placebo. Tirzepatide also demonstrated significant superiority across all 10 key secondary outcomes, including changes in BMI SD score, body weight, waist circumference, and physical functioning. Notably, 79.6% of participants…